4570 Pharmaceuticals & Biotechnology

GlaxoSmithKline plc Monitor

GlaxoSmithKline plc Annual Report 2018
CR Monitor Issue: 
2019/0618
Company covered: 
GlaxoSmithKline plc
Period End: 
31 December, 2018
Report issued on 19 June 2019 covered the following practice issues:
Pronouncements
Adoption of IFRS 15 Revenue from Contracts with Customers (IFRS 15) and IFRS 9 Financial Instruments (IFRS 9) from 1 January 2018.
Pronouncements
Disclosure in respect of the expected future impact of new accounting standard IFRS 16 Leases.
Change
Disclosure of events after the balance sheet date.
Change
A new section is added to the audit report covering the detection of irregularities including fraud.
Change
The equalisation of Guaranteed Minimum Pensions for men and women results in the recognition of a past service cost.
Change
Disclosure in respect of ‘transactions signed but not yet completed’ within the acquisitions and disposal note.

AstraZeneca Plc Monitor

AstraZeneca Plc Annual Report 2018
CR Monitor Issue: 
2019/0612
Company covered: 
AstraZeneca Plc
Period End: 
31 December, 2018
Report issued on 13 June 2019 covered the following practice issues:
Pronouncements
Adoption of IFRS 9 Financial Instruments, IFRS 15 Revenue from Contracts with Customers and IFRIC 22 Foreign Currency Transactions and Advance Consideration with effect from 1 January 2018.
Pronouncements
Disclosure in respect of future impacts of adoption of IFRIC 23 Uncertainty over Income Tax Treatments and IFRS 16 Leases has been provided.
Pronouncements
Disclosure in respect of Amendments to IFRS 2 Share-based Payments.
Change
Assets held for sale are disclosed separately within the statement of financial position.
Change
The equalisation of Guaranteed Minimum Pensions for men and women results in the recognition of a past service cost.
Change
Disclosures made in respect of post balance sheet events.

Vifor Pharma Ltd. Monitor

Vifor Pharma Ltd. Annual Report 2018
CR Monitor Issue: 
2019/0421
Company covered: 
Vifor Pharma Ltd.
Period End: 
31 December, 2018
Report issued on 26 April 2019 covered the following practice issues:
Pronouncements
Restatement of financial statement due to the adoption of IFRS 15 Revenue from contracts with customers.
Pronouncements
Disclosure in respect of the impact of IFRS 9 Financial instruments.
Pronouncements
Additional disclosure in respect of the expected impact of the new standard IFRS 16 Leases.
Change
Disclosure of a new share-based payment plan.
Change
Additional disclosure in respect of a review of actuarial assumptions.

Dechra Pharmaceuticals plc Monitor

Dechra Pharmaceuticals plc Annual Report 2018
CR Monitor Issue: 
2019/0115
Company covered: 
Dechra Pharmaceuticals plc
Period End: 
30 June, 2018
Report issued on 22 January 2019 covered the following practice issues:
Pronouncements
Disclosure in respect of the expected impact of new accounting standards including IFRS 9 "Financial instruments", IFRS 15 "Revenue from contracts with customers” and IFRS 16 “Leases”.
Change
Discussion of key audit matters included in the audit report including identification of a new key audit matter.
Change
Deferred tax changes recognised following changes to US tax legislation.
Change
Change in allocation of goodwill to cash generating units for impairment test purposes.
Change
Disclosure regarding remeasurement of contingent consideration.

Novartis Interims Monitor

Interim Financial Report
CR Interim Monitor Issue: 
2019/0105
Period End: 
30 June 2018
Listing Status: 
Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers
Pronouncements
Adoption of IFRS 9 "Financial instruments"
Pronouncements
Adoption of IFRS 15 "Revenue from contracts with customers".
Change
Changes made in segmental reporting following completion of an internal reorganisation.

Genus plc Monitor

Genus plc Annual Report 2018
CR Monitor Issue: 
2018/1119
Company covered: 
Genus plc
Period End: 
30 June, 2018
Report issued on 27 November 2018 covered the following practice issues:
Change
Reclassification in balance sheet as a result of "refining" biological assets accounting policy.
Pronouncements
Extended disclosure in respect of the future impacts of IFRS 15 "Revenue from contracts with customers", IFRS 16 "Leases"and IFRS 9 "Financial instruments.
Change
Revaluation of deferred tax liabilities following reduction in US corporate tax rate.
Change
Amounts linked to post balance sheet event recognised during the year.
Change
Changes made in segmental reporting disclosure.

Hikma Pharmaceuticals PLC Monitor

Hikma Pharmaceuticals PLC Annual Report 2017
CR Monitor Issue: 
2018/0918
Company covered: 
Hikma Pharmaceuticals PLC
Period End: 
31 December, 2017
Report issued on 24 September 2018 covered the following practice issues:
Change
Discussion of key audit matters included in audit report.
Change
Separate director and auditor responsibility sections included in audit report.
Pronouncements
Extended disclosure regarding the future impacts of IFRS 9 “Financial Instruments” and IFRS 15 “Revenue from Contracts with Customers”.
Change
Adoption of new disclosure format in respect of the other comprehensive income statement
Change
Recognition of significant impairment following testing of goodwill for impairment.
Change
Disclosure of impact of changes in US tax laws.

UCB SA Monitor

UCB SA Annual Report 2017
CR Monitor Issue: 
2018/0611
Company covered: 
UCB SA
Period End: 
31 December, 2017
Report issued on 19 June 2018 covered the following practice issues:
Pronouncements
Early adoption of IFRS 15 "Revenue from contracts with customers" using a full retrospective approach.
Pronouncements
Enhanced disclosure in respect of the future impacts of IFRS 16 "Leases".
Change
Fair value of previously held interest in business acquired taken into account in calculation of goodwill.
Pronouncements
Presentation of a reconciliation of movements in liabilities arising from financing activities on adoption of amendment to IAS 7 "Statement of cash flows".
Change
Discussion of key audit matters included in the auditors' report.
Change
Extended disclosure of principal risks including identification of a new risk factor.

Qiagen NV

Qiagen NV Annual Report 2017
CR Monitor Issue: 
2018/0602
Company covered: 
Qiagen NV
Period End: 
31 December, 2017
Report issued on 06 June 2018 covered the following practice issues:
Pronouncements
Extended discussion in respect of IFRS 15.
Change
Disclosure of impact of changes in US tax laws.
Change
Detailed disclosure of multi-tranche bond issue.
Change
Auditors identify bond issue as a key audit matter.

Roche Holding Ltd Monitor

Roche Holding Ltd Annual Report 2017
CR Monitor Issue: 
2018/0521
Company covered: 
Roche Holding Ltd
Period End: 
31st December 2017
Report issued on 29 May 2018 covered the following practice issues:
Pronouncements
Extended disclosure in respect of the future impacts of new accounting standards.
Change
Additional information disclosed in respect of provisions.
Change
Disclosure of IFRS 5 information linked to business disposals.
Change
Change in presentation of cash flows from investing activities.
Change
Calculation of goodwill linked to step acquisitions takes into account fair value of previously held interests.
Change
Newly acquired investment in associate accounted for using the equity method.